We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Horizon Therapeutics plans to expand its rare disease therapy portfolio through the purchase of Viela Bio in a deal valued at over $3 billion. Read More
Prescription drug prices that Americans pay are 156 percent higher than the combined average in 32 other countries that are also members of the Organization for Economic Co-operation and Development (OECD), the RAND Corporation has reported in an HHS-funded study. Read More
At least one major drug distributor could join the fray to ship COVID-19 vaccine shots across the country and offer some slack to McKesson, the firm currently handling distribution of Moderna’s vaccine, as a third vaccine candidate appears close to authorization. Read More
Novartis CEO Vas Narasimhan said the company is looking to help other companies scale up production of COVID-19 vaccines and treatments and is currently in talks with “key players.” Read More
Novavax has announced interim results from a phase 3 UK trial that showed its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated 89.3 percent efficacy but faltered in a separate study that evaluated the vaccine for the South Africa variant. Read More
The Federal Trade Commission (FTC) has filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories alleging that a 2017 agreement between the companies violated the antitrust laws by eliminating competition in the market for an extended release opioid, oxymorphone ER. Read More
Emergent Biosolutions has entered into an agreement to manufacture Humanigen’s lenzilumab, a potential treatment for COVID-19, ahead of an emergency use filing expected early this year. Read More
Civica Rx, a two-year-old nonprofit organization founded by hospitals and philanthropic groups to address generic drug shortages in the U.S., announced it will build its first manufacturing facility. Read More
Merus will spearhead the early development of oncology drugs, using its proprietary drug platform, while Eli Lilly’s Loxo Oncology subsidiary will provide additional research and marketing. Read More